viral specific cytotoxic t-lymphocytes

Phase 2

viral specific cytotoxic t-lymphocytes is one of 3 therapeutic programs targeting Cytomegalovirus Infections. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cytomegalovirus InfectionsRecruiting

Cytomegalovirus InfectionsPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Cytomegalovirus Infections

#DrugCompanyPhaseTrials

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

2 2

viral specific cytotoxic t-lymphocytes

NNew York Medical College

Phase 2

1 3

Viral Ctls

NNew York Medical College

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Cytomegalovirus Infections

NCT03266640

Clinical

Trials by Indication[1]

Cytomegalovirus Infections1 trial

A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections With Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Adult Recipients

Recruiting·NNew York Medical College·Phase 2·NCT03266640·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for viral specific cytotoxic t-lymphocytes. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for viral specific cytotoxic t-lymphocytes. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — New York Medical College company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: NNew York Medical College

viral specific cytotoxic t-lymphocytes

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Cytomegalovirus Infections1 trial

References

Drug Info

Quick Facts

Related News